The autoinjectors market are segmented into by Therapy (Anaphylaxis, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis and Other Therapies), Type (Reusable Autoinjectors and Disposable Autoinjectors), Route of Administration (Intramuscular, Subcutaneous), End-User (Hospitals & Clinics, Home Care Settings and Ambulatory Care Settings) and Region. Forty-six billion US dollars is the estimated market size of global autoinjectors during 2020. According to the studies, it is estimated to become 238.7 billion US dollars by 2030, with an increasing CAGR value of 17.9% from 2020 to 2030.
To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/autoinjectors-market
Critical Drivers accounting for the market growth:
The main key factors contributing to the growth of the global autoinjectors market are anaphylaxis, targeted therapies, and regulatory approvals. In addition, advancements in technology and an increase in chronic diseases requiring frequent consultation are the key factors that accounted for the increase in market growth.
By type of therapy used, "Rheumatoid Arthritis" held the maximum share during 2020
The autoinjectors market is further segmented into anaphylaxis, rheumatoid arthritis, multiple sclerosis, diabetes, and a few other categories such as migraine treatment, progesterone therapy, and cardiovascular diseases based on the therapy. Many cases of Rheumatoid Arthritis are the reason behind its significant growth of the market. In the United States, approximately 43.7 million adults, which constitute 22.7% of the total population, are affected by arthritis, thus increasing the demand for autoinjectors.
By type of autoinjectors used, "Disposable autoinjectors" held the maximum share during 2020
In contrast, disposable autoinjectors constituted for maximum market share during 2020 due to an increase in anaphylaxis and rheumatoid arthritis cases. Also, ease of use, simple administration, and rapid action of autoinjectors made it popular among patients and constituted for its growth.
By route of administration, "subcutaneous" held the maximum share during 2020
The autoinjectors market is further segmented into Intramuscular and Subcutaneous based on the route of administration. Usually, autoinjectors based on the route of administration, such as intramuscular and subcutaneous, are used for diseases such as anemia, multiple sclerosis, migraine, anaphylaxis, rheumatoid arthritis, diabetes, and cancer. Therefore, it is estimated that the subcutaneous segment will see rapid growth with a growing CAGR throughout the forecast period.
By end-user, "home care setting" held the maximum share during 2020
The autoinjectors market is further segmented into hospitals and clinics, home care settings, and ambulatory care settings. Home care settings had a significant market share during the forecasted period with a steady CAGR. The need for an affordable drug delivery system accounted for the rapid growth of home care setting segments.
By region, "North America" held the maximum share during 2020
The autoinjectors market is further segmented into North America, Asia Pacific, Europe, Latin America, Africa, and the Middle East. North America currently has a significant market share; increased diabetes and Rheumatoid Arthritis cases constituted the growth of this segment. The current market share is 41% approximately, while it is estimated to be growing at a CAGR of 19-22%.
Recent Developments in Autoinjectors Market Globally